SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaiS who wrote (12778)8/6/1998 6:01:00 PM
From: RT  Read Replies (1) of 23519
 
DaiS,

In the past I have voiced my concerns about the low refill numbers. I was told that the reason for the low refill numbers was because when a doctor writes a prescription he only writes it for so many refills (lets say 3) When the patients comes in for the forth refill it is in fact counted as a new script. Secondly if a person should go to a different pharmacy it will also be counted as a new script. If the doctor changes the dosage it is considered a new script. So basically the new vs refills doesn't mean much. The total scripts sold is the all important number.

It's obvious that after 600K users the product has a very low acceptance rate. Now maybe worldwide demand might keep the factory's humming but overall the product needs help, just like the shit heads running the company. Disgusted beyond belief.

RT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News